Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871142/0/en/Cognition-Therapeutics-Completes-Enrollment-in-Phase-2-SHIMMER-Study-of-CT1812-in-Mild-to-Moderate-Dementia-with-Lewy-Bodies.html

PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that the company has reached target enrollment in the randomized, placebo-controlled Phase 2 SHIMMER (COG1201) study (NCT05225415), which is examining the safety and effectiveness of CT1812 in adults with mild-to-moderate dementia with Lewy bodies (DLB). Top-line results are expected in the second half of 2024 after the last participants have completed six months of treatment.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.